Sargent Investment Group »

Revance Therapeutics shares owned by Sargent Investment Group

Quarter-by-quarter ownership of Revance Therapeutics (RVNC) shares owned by Sargent Investment Group from 13F filings

Historical chart of Sargent Investment Group investment in Revance Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Revance Therapeutics held by Sargent Investment Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Revance Therapeutics by Sargent Investment Group

Quarter filed Position value Share count Share price at filing
2023-12-31 $122k 14k 8.79

More positions owned by Sargent Investment Group

Spdr Ser Tr Bloomberg 3-12 M (BILS)
Apple (AAPL)
Microsoft Corporation (MSFT)
First Tr Exchange Traded Nasdaq Cyb Etf (CIBR)
Cantaloupe (CTLP)
Universal Display Corporation (OLED)
Blackstone Group Inc Com Cl A (BX)
Carlyle Group (CG)
First Tr Exchange-traded Cap Strength Etf (FTCS)
Palantir Technologies Cl A (PLTR)
Spdr Ser Tr Prtflo S&p500 Gw (SPYG)
International Business Machines (IBM)
Iron Mountain (IRM)
Spdr Ser Tr Prtflo S&p500 Vl (SPYV)
Amazon (AMZN)

View all positions for Sargent Investment Group

Top funds holding Revance Therapeutics

Palo Alto Investors
Vanguard Group
Franklin Resources
Jpmorgan Chase & Co
Jennison Associates
Bamco
Walleye Trading Advisors
Goldman Sachs Group
Rice Hall James & Associates
Charles Schwab Investment Management
Citadel Advisors
Wellington Management Company
D. E. Shaw & Co
HighTower Advisors
Balyasny Asset Management

View all funds holding Revance Therapeutics